Cargando…

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod

OBJECTIVE: Lymphopenia is a common occurrence of disease-modifying therapies (DMTs) for relapsing-remitting MS (RRMS). The aim of this study was to dissect the prevalence of various lymphocyte subsets in patients with RRMS treated with 2 DMTs commonly associated with lymphopenia, dimethyl fumarate (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakhaei-Nejad, Maryam, Barilla, David, Lee, Chieh-Hsin, Blevins, Gregg, Giuliani, Fabrizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746425/ https://www.ncbi.nlm.nih.gov/pubmed/29296636 http://dx.doi.org/10.1212/NXI.0000000000000432

Ejemplares similares

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
Publicado: (2018)

Dimethyl fumarate–induced lymphopenia in MS due to differential T-cell subset apoptosis
por: Ghadiri, Mahtab, et al.
Publicado: (2017)

Immunological Predictors of Dimethyl Fumarate‐Induced Lymphopenia
por: Diebold, Martin, et al.
Publicado: (2022)

Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance
por: Longbrake, Erin E, et al.
Publicado: (2015)

Genetic Study of Severe Prolonged Lymphopenia in Multiple Sclerosis Patients Treated With Dimethyl Fumarate
por: Sangurdekar, Dipen, et al.
Publicado: (2019)

Impaired T-cell migration to the CNS under fingolimod and dimethyl fumarate
por: Mathias, Amandine, et al.
Publicado: (2017)

Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers
por: Vollmer, Brandi, et al.
Publicado: (2018)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
por: Wicks, Paul, et al.
Publicado: (2016)

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience
por: Vollmer, Brandi, et al.
Publicado: (2017)

HDL-cholesterol elevation associated with fingolimod and dimethyl fumarate therapies in multiple sclerosis
por: Blumenfeld Kan, S, et al.
Publicado: (2019)

Dimethyl fumarate vs fingolimod following different pretreatments: A retrospective study
por: Diem, Lara, et al.
Publicado: (2020)

The effects of dimethyl fumarate and fingolimod on T-cell lymphocyte proliferation in patients with multiple sclerosis
por: Reynolds, Audrey, et al.
Publicado: (2022)

Effect of tobacco use on disease activity and DMT discontinuation in multiple sclerosis patients treated with dimethyl fumarate or fingolimod
por: Hersh, Carrie M, et al.
Publicado: (2020)

Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis
por: Hou, Jue, et al.
Publicado: (2021)

Risk factors for fingolimod-induced lymphopenia in multiple sclerosis
por: Ohtani, Ryohei, et al.
Publicado: (2018)

CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient
por: Kogel, Ann-Kathrin, et al.
Publicado: (2021)

Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis
por: Lucchini, Matteo, et al.
Publicado: (2021)

Anti-John Cunningham virus antibody index levels in multiple sclerosis patients treated with rituximab, fingolimod, and dimethyl fumarate
por: Farley, Stephen, et al.
Publicado: (2019)

A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod
por: Salter, Amber, et al.
Publicado: (2021)

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up
por: Hersh, Carrie M, et al.
Publicado: (2017)

Therapeutic Potential of Fingolimod and Dimethyl Fumarate in Non-Small Cell Lung Cancer Preclinical Models
por: Rupp, Tristan, et al.
Publicado: (2022)

Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis
por: Diebold, Martin, et al.
Publicado: (2022)

Erratum to “A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod”
Publicado: (2021)

Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS: Patient management considerations
por: Fox, Robert J., et al.
Publicado: (2016)

Comparison of dimethyl fumarate and interferon outcomes in an MS cohort
por: Sattarnezhad, Neda, et al.
Publicado: (2022)

Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age
por: Briner, Myriam, et al.
Publicado: (2019)

Patient-specific factors modulate leukocyte response in dimethyl fumarate treated MS patients
por: Goldman, Myla D., et al.
Publicado: (2020)

Fingolimod: Lymphopenia and COVID-19 infection complicated by pneumonia: case report
Publicado: (2020)

Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series
por: Delgado, Silvia, et al.
Publicado: (2021)

Mononuclear cell transcriptome changes associated with dimethyl fumarate in MS
por: Gafson, Arie R., et al.
Publicado: (2018)

Primary cutaneous cryptococcal infection due to fingolimod – Induced lymphopenia with literature review
por: Patil, Sachin M., et al.
Publicado: (2020)

Dimethyl fumarate for treating Papillon–Lefèvre syndrome
por: Al-Omair, Abdullah, et al.
Publicado: (2022)

Intracerebral lymphoproliferative disorder in an MS patient treated with fingolimod
por: de Jong, Brigit A., et al.
Publicado: (2018)

Lymphopenia and DMTs for relapsing forms of MS: Considerations for the treating neurologist
por: Fox, Edward J., et al.
Publicado: (2019)

Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics
por: Hersh, Carrie M, et al.
Publicado: (2022)

Dimethyl fumarate alters B‐cell memory and cytokine production in MS patients
por: Smith, Matthew D., et al.
Publicado: (2017)

A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry
por: Hillert, Jan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_irq3ru17ps8mg6tajpg7kej7bs